Shuttle Pharma prelim FY2025 net loss widens to ~$11-12M; G&A up 3.6x on investor ads

Shuttle Pharmaceuticals Holdings, Inc.

2025-FY EPS reported -$7.16

Preliminary FY2025 net loss expected between $10.9M and $12.1M vs $9.1M in FY2024; revenue remains zero.
G&A expense surged to $5.2-5.8M from $1.4M, driven by $3.6M in investor relations advertising costs.
Working capital turns negative to deficit of $0.7-0.8M from positive $0.7M; cash used for Molecule.ai acquisition and trial wind-down.
Intangible assets of $9.8M from Molecule.ai acquisition; contingent consideration of $2.0M and consideration payable of $4.4M.
All convertible notes converted to stock; company needs additional financing to continue as going concern.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.